ASC-21

N/A

Report date: 2022/07/19 14:58:25
NME

Base Information

Drug NameASC-21
Drug Alias NameASC-21MIV-802
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMedivir AB
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTrek TherapeuticsAscletis Biological Pharmaceutical (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis C
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A